Form 144 FENNEC PHARMACEUTICALS INC. For: 1 July
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fennec Pharmaceuticals Inc (FRX)
The Fennec Pharma share price today is 13.85, view TSX FRX stock exchange data. Track the latest Fennec Pharma share price with real-time updates on FRX stock performance including market cap, day range, 52-week range and dividend yield. Access FRX charts, earnings dates and analyst estimates to support your investment decisions.
13.85
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.85
13.85
52 wk Range
7.59
15.48
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.8513.85
52 wk Range
7.5915.48
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Form 13G FENNEC PHARMACEUTICALS INC. For: 15 May- Investing.com
Form 144 FENNEC PHARMACEUTICALS INC. For: 1 June- Investing.com
Form 13G FENNEC PHARMACEUTICALS INC. For: 14 May- Investing.com
- Form 144 FENNEC PHARMACEUTICALS INC. For: 1 July
- Investing.com
- Form 144 FENNEC PHARMACEUTICALS INC. For: 1 June
- Investing.com
Form 8K FENNEC PHARMACEUTICALS INC. For: 18 May- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Earnings
Latest Release
14-05-2026
EPS / Forecast
0.01 / -0.04
Revenue / Forecast
15.1M / 14.65M
Compare FRX to Peers and Sector
Metrics to compare | FRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −39.7x | −1.3x | −0.3x | |
PEG Ratio | −0.84 | −0.05 | 0.00 | |
Price/Book | 8.8x | 1.7x | 2.6x | |
Price / LTM Sales | 6.5x | 10.0x | 3.0x | |
Upside (Analyst Target) | - | 194.8% | 56.7% | |
Fair Value Upside | Unlock | 17.7% | 9.4% | Unlock |
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Fennec Pharma (FRX) Share Price Today?
The Fennec Pharma share price today is 13.85.
What is the current Fennec Pharma (FRX) share price and day range?
As of 01-08-2026, the Fennec Pharma share price is 13.85, with a previous close of 13.85. The share price has ranged from 13.85 to 13.85 today, while the 52-week range spans from 7.59 to 15.48.
What Is the Fennec Pharma Market Cap?
As of today, Fennec Pharma market cap is 482.46M.
What Is Fennec Pharma's Earnings Per Share (TTM)?
The Fennec Pharma EPS (TTM) is -0.28.
When Is the Next Fennec Pharma Earnings Date?
Fennec Pharma will release its next earnings report on 06-08-2026.
From a Technical Analysis Perspective, Is FRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Fennec Pharma Trade On?
Fennec Pharma is listed and trades on the Toronto Stock Exchange.
What Is the Stock Symbol for Fennec Pharma?
The stock symbol for Fennec Pharma is "FRX."
How Many Times Has Fennec Pharma Stock Split?
Fennec Pharma has split 3 times.
How Many Employees Does Fennec Pharma Have?
Fennec Pharma has 35 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.